Abstract
Candida albicans is the most common nosocomial systemic fungal infections causing high mortality/morbidity. Existing antifungal treatment regime is feeble due to persistent multiple drug resistance. There is an ardent need for novel drug targets that replace the generic ones is extremely crucial. Subtractive proteomics approach was used for qualitative characterization/identification of possible drug targets. For identification of novel targets, the entire set of proteome of C. albicans (6035 proteins) was collected from NCBI and shortlisted through curtailment proteome analysis. The analysis revealed that only a few proteins were non-homologous to humans whereas some proteins were essential metabolic proteins. The identification of novel protein targets in C. albicans was successfully identified and shortlisted by using a subtractive proteome analysis approach. Among those 64 proteins, authors report that 11 drug targets participated in a pathway leading to virulence. All proteins were recognized as cytoplasmic proteins and could be treated as important/promising antifungal drug targets with putative druggable properties because cytoplasmic proteins are considered as good druggable targets. The novel drug targets that we are reporting in this study will help to broaden and contribute towards promising antifungal therapy and drug discovery against C. albicans infections.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: International Journal of Peptide Research and Therapeutics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.